<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018108</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 17108</org_study_id>
    <nct_id>NCT01018108</nct_id>
  </id_info>
  <brief_title>Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors</brief_title>
  <official_title>Effect of Acupuncture on Brain Serotonin Among Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: New imaging procedures, such as single photon emission computed tomography, may&#xD;
      help in learning how acupuncture affects serotonin levels in the brain of breast cancer&#xD;
      survivors. PURPOSE: This phase I trial is studying the best way to visualize the effect of&#xD;
      acupuncture on brain serotonin in breast cancer survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility of using [123-I] ADAM Serotonin transporter (SERT) binding as&#xD;
      a putative biomarker to visualize the mechanism of effects of acupuncture for hot flashes&#xD;
      involving serotonin.&#xD;
&#xD;
      OUTLINE: Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6&#xD;
      weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I&#xD;
      ADAM before and after completion of acupuncture.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SERT uptake ratios</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Hot flash composite score (HFCS)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hot flash related daily interference scale (HFRDIS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index (PSQI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Fatigue Inventory (BFI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hot flash frequency and severity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acupuncture expectancy scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Credibility rating of acupuncture</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo single photon emission computed tomographt imaging</description>
    <arm_group_label>I</arm_group_label>
    <other_name>SPECT imaging, tomography, emission computed, single photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture Therapy</intervention_name>
    <description>Undergo acupuncture</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Acupuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary study</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative Study</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of Stage I, II, or III breast cancer for at least 12 months&#xD;
&#xD;
          -  Have been seen by an oncologist within the previous 6-month period and determined to&#xD;
             be free of disease by clinical examination and history&#xD;
&#xD;
          -  Have been receiving endocrine therapy (tamoxifen or aromatase inhibitors for at least&#xD;
             four weeks)&#xD;
&#xD;
          -  Experienced hot flashes with a hot flash composite score of 5 or greater per day&#xD;
&#xD;
          -  Hot flashes have been present for at least a month before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently on chemotherapy or radiation therapy as adjuvant treatment&#xD;
&#xD;
          -  Started with hormonal therapies such as tamoxifen or aromatase inhibitors within the&#xD;
             last 4 weeks; or plan to change or terminate hormonal therapies in the next 14 weeks&#xD;
&#xD;
          -  Any history of use of psychotropic medication such as SSRI use for the past 6 months&#xD;
&#xD;
          -  Any past use of centrally acting medications such as clonidine for the past 6 months&#xD;
&#xD;
          -  Any past diagnosis of a Major Depressive Episode within the last 6 months&#xD;
&#xD;
          -  Any allergy to iodine or shell-fish or radio-nuclear materials&#xD;
&#xD;
          -  Current use of estrogen and/or progestin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Women of child-bearing potential NOT willing to use a medically acceptable form of&#xD;
             contraception&#xD;
&#xD;
          -  Current use of any anti-convulsant such as gabapentin&#xD;
&#xD;
          -  History of cerebral infarction (including lacunar infarct with symptoms &gt;= 24 hours&#xD;
             duration)&#xD;
&#xD;
          -  History of Binswanger's disease (or a history of hypertensive encephalopathy)&#xD;
&#xD;
          -  History of intracranial hemorrhage&#xD;
&#xD;
          -  History of head trauma with loss of consciousness&#xD;
&#xD;
          -  History of encephalitis&#xD;
&#xD;
          -  History of extended exposure to known neurotoxin (e.g., cyanide, carbon monoxide)&#xD;
&#xD;
          -  Uncontrolled metabolic disorder (e.g., thyroid disease, diabetes mellitus)&#xD;
&#xD;
          -  History of normal pressure hydrocephalus&#xD;
&#xD;
          -  History of Parkinson's or other basal ganglia disease&#xD;
&#xD;
          -  History of substance abuse in the previous 6 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Mao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

